Protective effects of valsartan against cigarette smoke-induced left ventricular systolic dysfunction in rats

International Journal of Cardiology

Volumn 167, Issue 3, 2013, Pages 677-680

  Zhou, Xiang ^a   Li, Chao ^b   Xu, Weiting ^a   Chen, Jianchang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Inflammation; Left ventricular systolic dysfunction; Oxidative stress; Smoking; Valsartan

Indexed keywords

C REACTIVE PROTEIN; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; LIPOCORTIN 5; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SMOKING; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE;

APOPTOSIS; INFLAMMATION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; OXIDATIVE STRESS; SMOKING; VALSARTAN;

ANIMALS; CARDIOTONIC AGENTS; INFLAMMATION MEDIATORS; MALE; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SMOKING; TETRAZOLES; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84880922604     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.03.068     Document Type: Article

References (33)

1. J.B. Lakier Smoking and cardiovascular disease Am J Med 93 1992 8S 12S
2. D.M. Burns Epidemiology of smoking-induced cardiovascular disease Prog Cardiovasc Dis 46 2003 11 29
3. J. He, S. Vupputuri, K. Allen, M.R. Prerost, J. Hughes, and P.K. Whelton Passive smoking and the risk of coronary heart disease - a meta-analysis of epidemiologic studies N Engl J Med 340 1999 920 926
4. K.K. Teo, S. Ounpuu, and S. Hawken Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study Lancet 368 2006 647 658
5. X. Zhou, Y. Sheng, R. Yang, and X. Kong Nicotine promotes cardiomyocyte apoptosis via oxidative stress and altered apoptosis-related gene expression Cardiology 115 2010 243 250
6. L.T. Skeggs, F.E. Dorer, J.R. Kahn, K.E. Lentz, and M. Levine The biochemistry of the renin-angiotensin system and its role in hypertension Am J Med 60 1976 737 748
7. S. Mochizuki, B. Dahlöf, and M. Shimizu Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study Lancet 369 2007 1431 1439
8. J.N. Cohn, and G. Tognoni Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
9. H. Suzuki, E. Geshi, and S. Nanjyo Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study Circ J 73 2009 918 924
10. R.O. Estacio, J.R. Coll, Z.V. Tran, and R.W. Schrier Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes Am J Hypertens 19 2006 1241 1248
11. X.D. Wang, C. Liu, R.T. Bronson, D.E. Smith, N.I. Krinsky, and R.M. Russel Retinoid signaling and activator protein-1 expression in ferrets given b-carotene supplements and exposure to tobacco smoke J Natl Cancer Inst 91 1999 60 66
12. N.B. Schiller, P.M. Shah, and M. Crawford Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-dimensional Echocardiograms J Am Soc Echocardiogr 2 1989 358 367
13. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal Biochem 95 1979 351 358
14. Y. Sun, L.W. Oberley, and Y. Li A simple method for clinical assay of superoxide dismutase Clin Chem 34 1988 497 500
15. D.E. Paglia, and W.N. Valentine Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase J Lab Clin Med 70 1967 158 169
16. S.R. Heckbert, W. Post, and G.D. Pearson Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis J Am Coll Cardiol 48 2006 2285 2292
17. M. Hori, and K. Nishida Oxidative stress and left ventricular remodelling after myocardial infarction Cardiovasc Res 81 2009 457 464
18. K.C. Lord, S.K. Shenouda, E. McIlwain, D. Charalampidis, P.A. Lucchesi, and K.J. Varner Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction Cardiovasc Res 87 2010 111 118
19. D.B. Sawyer, D.A. Siwik, L. Xiao, D.R. Pimentel, K. Singh, and W.S. Colucci Role of oxidative stress in myocardial hypertrophy and failure J Mol Cell Cardiol 34 2002 379 388
20. F.J. Giordano Oxygen, oxidative stress, hypoxia, and heart failure J Clin Invest 115 2005 500 508
21. A.V. Zima, and L.A. Blatter Redox regulation of cardiac calcium channels and transporters Cardiovasc Res 71 2006 310 321
22. A. Sabri, H.H. Hughie, and P.A. Lucchesi Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes Antioxid Redox Signal 5 2003 731 740
23. T.H. Cheng, P.Y. Cheng, N.L. Shih, I.B. Chen, D.L. Wang, and J.J. Chen Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts J Am Coll Cardiol 42 2003 1845 1854
24. D.A. Siwik, P.J. Pagano, and W.S. Colucci Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts Am J Physiol Cell Physiol 280 2001 C53 C60
25. A. Baldi, A. Abbate, and R. Bussani Apoptosis and post-infarction left ventricular remodeling J Mol Cell Cardiol 34 2002 165 174
26. V.P. van Empel, A.T. Bertrand, L. Hofstra, H.J. Crijns, P.A. Doevendans, and L.J. De Windt Myocyte apoptosis in heart failure Cardiovasc Res 67 2005 21 29
27. W. Ibe, A. Saraste, and S. Lindemann Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment Eur J Heart Fail 9 2007 160 167
28. G. Condorelli, C. Morisco, and G. Stassi Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat Circulation 99 1999 3071 3078
29. D. Hasper, M. Hummel, F.X. Kleber, I. Reindl, and H.D. Volk Systemic inflammation in patients with heart failure Eur Heart J 19 1998 761 765
30. G. Torre-Amione, S. Kapadia, C. Benedict, H. Oral, J.B. Young, and D.L. Mann Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD) J Am Coll Cardiol 27 1996 1201 1206
31. M. Matsumoto, T. Tsujino, and M. Lee-Kawabata Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction Cytokine 49 2010 264 268
32. B. Bozkurt, S.B. Kribbs, and F.J. Clubb Jr. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats Circulation 97 1998 1382 1391
33. J. Iwasaki, K. Nakamura, and H. Matsubara Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy Cardiovasc Pathol 18 2009 317 322